Innovent Biologics (HK:1801) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovent Biologics, a biopharmaceutical company, has announced changes to its board committees, effective August 30, 2024. Dr. De-Chao Michael Yu has transitioned from chairman to member of the Nomination Committee, stepping down from the Remuneration Committee. Mr. Shuyun Chen moves from member to chairman of the Nomination Committee and joins the Audit Committee.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.